title: Expression of antimicrobial peptides and proteins in etanercept-treated psoriasis patients.
abstract: Recent papers highlight the role of dysregulated expression of antimicrobial peptides and proteins (AMPs) in the pathogenesis of psoriasis. Etanercept, a blocker of the pro-inflammatory cytokine tumour necrosis factor-α (TNF-α), is effective in the treatment of psoriasis. We aimed to evaluate the expression profiles of AMPs in psoriatic skin before and after a 6-week course of etanercept therapy. We included 12 psoriasis patients who underwent medium-dose etanercept treatment for 6weeks. At baseline and at the end of therapy immunohistochemistry from lesional skin was performed for psoriasin, LL-37, and human ß-defensin 2 (hBD-2). After 6-week treatment, the modified psoriasis area and severity index significantly decreased from 37.5±5.9 to 14±13.4. Lesional immunoreactivity scores of psoriasin, LL-37, and hBD-2 also significantly decreased after a 6-week course of etanercept. We have demonstrated that etanercept-induced improvement of psoriasic lesions is associated with a significant decline of AMP protein expression.
authors.affiliation: Department of Dermatology, Ruhr-University Bochum, Germany. t.gambichler@klinikum-bochum.de
authors.forename: T
authors.initials: T
authors.lastname: Gambichler
authors.forename: S
authors.initials: S
authors.lastname: Kobus
authors.forename: A
authors.initials: A
authors.lastname: Kobus
authors.forename: C
authors.initials: C
authors.lastname: Tigges
authors.forename: N
authors.initials: N
authors.lastname: Scola
authors.forename: P
authors.initials: P
authors.lastname: Altmeyer
authors.forename: A
authors.initials: A
authors.lastname: Kreuter
authors.forename: F G
authors.initials: FG
authors.lastname: Bechara
authors.forename: M
authors.initials: M
authors.lastname: Skrygan
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D023181:Antimicrobial Cationic Peptides / Q000378:metabolism*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D000075023:S100 Calcium Binding Protein A7; D009418:S100 Proteins / Q000378:metabolism; D023083:beta-Defensins / Q000378:metabolism; D054804:Cathelicidins
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D023181:Antimicrobial Cationic Peptides; C106641:DEFB4A protein, human; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000075023:S100 Calcium Binding Protein A7; D009418:S100 Proteins; C089242:S100A7 protein, human; D023083:beta-Defensins; D000068800:Etanercept; D054804:Cathelicidins